B+
Bull case
25%
Probability
Target price
$96.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
ANIP
ANIANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$78.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$61.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-17
Recent news sentiment (30D)
+55.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+78.6
Score
AI commentary
News tone is mixed: Q2 operating results were strong and total-year guidance was reaffirmed, but the Cortrophin outlook adjustment remains an overhang. The packet lacks reliable post-print analyst revisions and social coverage, so sentiment confidence is limited.
RankAlpha Sentiment Codex - 2026-08-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-17eventQ2 results showed strong operating executionMedium impact
ANI reported record Q2 revenue of $266.0 million, Cortrophin Gel revenue of $117.1 million, adjusted EBITDA of $71.6 million, and reaffirmed 2026 total revenue and EBITDA guidance [#8-K-2026-08-07][#SEC-8K-2026-08-07].
2026-08-17catalystCortrophin guidance adjustment remains an overhangHigh impact
Management modestly adjusted full-year Cortrophin Gel revenue guidance to $520-$540 million while ILUVIEN revenue declined 16.1% year over year, increasing sensitivity to commercial execution [#SEC-8K-2026-08-07].
2026-09-30catalystGout expansion could drive second-half Cortrophin growthHigh impact
The gout-focused commercial expansion was fully operational by June, with positive early demand indicators and a record number of new cases initiated in July [#SEC-8K-2026-08-07][#PR-EARNINGS-2026-08-14].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-17 • Updated nightlySource: Internal modelMethodology